The compounds, developed in partnership with researchers at the University of Durham, UK, have unusual side chains that give them different properties than the amino acids on which they are based.
This ‘unusualness’ may give peptide and protein-based drugs made using the amino acids novel therapeutic characteristics, potentially improving the efficacy of existing products or enabling researchers to develop completely unique treatments.
Onyx CEO Tony Flinn said: “Our alliance with Durham University has been a very successful one in that it has led to the development of a completely novel range of amino acids with unusual side chains for research applications. We can now offer these products to the market on a small scale along with the potential for scale-up to larger quantities using our facilities.”
This was echoed by Steven Cobb, from the department of chemistry at Durham University, who added that: “The amino acids prepared have a range of applications not just in peptide chemistry but also as precursors for biological feeding experiments and as novel building blocks in natural product chemistry.”